Sign Up Today and Learn More About Human Immunology Biosciences Stock
Invest in or calculate the value of your shares in Human Immunology Biosciences or other pre-IPO companies through EquityZen's platform.
Human Immunology Biosciences Stock
Human Immunology Biosciences is a biotechnology company focused on developing therapies for immune-mediated diseases.
About Human Immunology Biosciences Stock
Founded
2021
Headquarters
San Francisco, CA, US
Industries
Data and Analytics, Science and Engineering, Health Care
Human Immunology Biosciences Press Mentions
Stay in the know about the latest news on Human Immunology Biosciences
Jeito Capital sells HI-Bio for $1.8bn
realdeals • May 27, 2024
HI-Bio to Present at the 61st European Renal Association (ERA) Congress
prnewswire • May 23, 2024
Biogen: agreement to acquire HI-Bio
marketscreener • May 23, 2024
HI-Bio on LinkedIn: #lupusawarenessmonth #worldlupusday
linkedin • May 20, 2024
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection ...
prnewswire • Apr 07, 2024
Human Immunology Biosciences Management
Leadership team at Human Immunology Biosciences
Chief Translational Officer
Matthew Albert
Chief Business Officer
Carl Enell
Join now and verify your accreditation status to gain access to:
- Human Immunology Biosciences current valuation
- Human Immunology Biosciences stock price
- Available deals in Human Immunology Biosciences and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Human Immunology Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Human Immunology Biosciences through EquityZen funds. These investments are made available by existing Human Immunology Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Human Immunology Biosciences stock?
Shareholders can sell their Human Immunology Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
